Tumor Biology

, Volume 35, Issue 4, pp 3447–3453 | Cite as

Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis

  • Thaís Brilhante Pontes
  • Elizabeth Suchi Chen
  • Carolina Oliveira Gigek
  • Danielle Queiroz Calcagno
  • Fernanda Wisnieski
  • Mariana Ferreira Leal
  • Samia Demachki
  • Paulo Pimentel Assumpção
  • Ricardo Artigiani
  • Laércio Gomes Lourenço
  • Rommel Rodriguez Burbano
  • Marília Arruda Cardoso SmithEmail author
Research Article


Aberrant methylation has been reported in several neoplasias, including gastric cancer. The methyl-CpG-binding domain (MBD) family proteins have been implicated in the chromatin remodeling process, leading to the modulation of gene expression. To evaluate the role of MBD2 and MBD3 in gastric carcinogenesis and the possible association with clinicopathological characteristics, we assessed the mRNA levels and promoter methylation patterns in gastric tissues. In this study, MBD2 and MBD3 mRNA levels were determined by RT-qPCR in 28 neoplastic and adjacent nonneoplastic and 27 gastritis and non-gastritis samples. The promoter methylation status was determined by bisulfite sequencing, and we found reduced MBD2 and MBD3 levels in the neoplastic samples compared with the other groups. Moreover, a strong correlation between the MBD2 and MBD3 expression levels was observed in each set of paired samples. Our data also showed that the neoplastic tissues exhibited higher MBD2 promoter methylation than the other groups. Interestingly, the non-gastritis group was the only one with positive methylation in the MBD3 promoter region. Furthermore, a weak correlation between gene expression and methylation was observed. Therefore, our data suggest that DNA methylation plays a minor role in the regulation of MBD2 and MBD3 expression, and the presence of methylation at CpGs that interact with transcription factor complexes might also be involved in the modulation of these genes. Moreover, reduced mRNA expression of MBD2 and MBD3 is implicated in gastric carcinogenesis, and thus, further investigations about these genes should be conducted for a better understanding of the role of abnormal methylation involved in this neoplasia.


Methyl-binding domain proteins Gastric cancer DNA methylation Gene expression 



This research was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil), Coordenadoria de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES, Brazil), and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Brazil).

Conflict of interests



  1. 1.
    Jemal A et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S17–25. e1-3.PubMedGoogle Scholar
  2. 2.
    Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266(2):99–115.PubMedCrossRefGoogle Scholar
  3. 3.
    Calcagno DQ et al. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol. 2013;19(8):1182–92.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Gigek CO et al. Epigenetic mechanisms in gastric cancer. Epigenomics. 2012;4(3):279–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Bogdanovic O, Veenstra GJ. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma. 2009;118(5):549–65.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Saito M, Ishikawa F. The mCpG-binding domain of human MBD3 does not bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem. 2002;277(38):35434–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang Y et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 1999;13(15):1924–35.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Le Guezennec X et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 2006;26(3):843–51.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Ballestar E et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003;22(23):6335–45.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Lai AY, Wade PA. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat Rev Cancer. 2011;11(8):588–96.PubMedCrossRefGoogle Scholar
  11. 11.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Immunol Scand. 1965;64:31–49.Google Scholar
  12. 12.
    Wisnieski F et al. Reference genes for quantitative RT-PCR data in gastric tissues and cell lines. World J Gastroenterol. 2013;19(41):7121–8.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.Google Scholar
  14. 14.
    Carr IM et al. Sequence analysis and editing for bisulphite genomic sequencing projects. Nucleic Acids Res. 2007;35(10):e79.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Farre D et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003;31(13):3651–3.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Messeguer X et al. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18(2):333–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Lopez-Serra L et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene. 2008;27(25):3556–66.PubMedCrossRefGoogle Scholar
  18. 18.
    Parry L, Clarke AR. The roles of the methyl-CpG binding proteins in cancer. Cancer Gene Ther. 2011;2(6):618–30.CrossRefGoogle Scholar
  19. 19.
    Sansom OJ, Maddison K, Clarke AR. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol. 2007;4(5):305–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Amir RE et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Calcagno DQ et al. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol. 2013;19(8):1182–92.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Muller-Tidow C et al. Loss of expression of HDAC-recruiting methyl-CpG-binding domain proteins in human cancer. Br J Cancer. 2001;85(8):1168–74.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Kanai Y et al. Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers. Biochem Biophys Res Commun. 1999;264(3):962–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Maekita T et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12(3 Pt 1):989–95.PubMedCrossRefGoogle Scholar
  25. 25.
    Lima EM et al. Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res. 2008;41(6):539–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Gigek CO et al. Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma. Growth Horm IGF Res. 2010;20(3):234–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Leal MF et al. Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from northern Brazil. World J Gastroenterol. 2007;13(18):2568–74.PubMedGoogle Scholar
  28. 28.
    Gigek CO et al. hTERT methylation and expression in gastric cancer. Biomarkers. 2009;14(8):630–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Angrisano T et al. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res. 2006;34(1):364–72.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Chatagnon A et al. Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis. 2009;30(1):28–34.PubMedCrossRefGoogle Scholar
  31. 31.
    Hendrich B et al. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 2001;15(6):710–23.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Kaji K et al. The NuRD component Mbd3 is required for pluripotency of embryonic stem cells. Nat Cell Biol. 2006;8(3):285–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Aguilera C et al. c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature. 2011;469(7329):231–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Sato M et al. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. Oncogene. 2002;21(31):4822–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Liu C et al. Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knock-down by stable RNA interference. BMC Cancer. 2008;8:121.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Luo G et al. RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles. Cancer Biol Ther. 2009;8(7):594–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 1998;18(11):6538–47.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Gunther K et al. Differential roles for MBD2 and MBD3 at methylated CpG islands, active promoters and binding to exon sequences. Nucleic Acids Res. 2013;41(5):3010–21.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Brackertz M et al. Two highly related p66 proteins comprise a new family of potent transcriptional repressors interacting with MBD2 and MBD3. J Biol Chem. 2002;277(43):40958–66.PubMedCrossRefGoogle Scholar
  40. 40.
    Tatematsu KI, Yamazaki T, Ishikawa F. MBD2-MBD3 complex binds to hemi-methylated DNA and forms a complex containing DNMT1 at the replication foci in late S phase. Genes Cells. 2000;5(8):677–88.PubMedCrossRefGoogle Scholar
  41. 41.
    Watabe Y et al. Aryl hydrocarbon receptor functions as a potent coactivator of E2F1-dependent trascription activity. Biol Pharm Bull. 2010;33(3):389–97.PubMedCrossRefGoogle Scholar
  42. 42.
    Xanthoulis A, Tiniakos DG. E2F transcription factors and digestive system malignancies: how much do we know? World J Gastroenterol. 2013;19(21):3189–98.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Consortium EP et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.CrossRefGoogle Scholar
  44. 44.
    Chen YJ et al. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. World J Gastroenterol. 2012;18(29):3849–61.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Yuan K et al. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Am J Gastroenterol. 2013;145(4):853–64. e9.Google Scholar
  46. 46.
    Zhang X et al. MicroRNA-373 is upregulated and targets TNFAIP1 in human gastric cancer, contributing to tumorigenesis. Oncol Lett. 2013;6(5):1427–34.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Liu K et al. Increased expression of MicroRNA-221 in gastric cancer and its clinical significance. J Int Med Res. 2012;40(2):467–74.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Thaís Brilhante Pontes
    • 1
  • Elizabeth Suchi Chen
    • 1
  • Carolina Oliveira Gigek
    • 1
  • Danielle Queiroz Calcagno
    • 1
  • Fernanda Wisnieski
    • 1
  • Mariana Ferreira Leal
    • 1
  • Samia Demachki
    • 2
  • Paulo Pimentel Assumpção
    • 3
  • Ricardo Artigiani
    • 4
  • Laércio Gomes Lourenço
    • 5
  • Rommel Rodriguez Burbano
    • 6
  • Marília Arruda Cardoso Smith
    • 1
    Email author
  1. 1.Disciplina de Genética, Departamento de Morfologia e GenéticaUniversidade Federal de São PauloSão PauloBrazil
  2. 2.Serviço de Patologia, Hospital Universitário João de Barros BarretoUniversidade Federal do ParáBelémBrazil
  3. 3.Serviço de Cirurgia, Hospital Universitário João de Barros BarretoUniversidade Federal do ParáBelémBrazil
  4. 4.Departamento de PatologiaUniversidade Federal de São PauloSão PauloBrazil
  5. 5.Disciplina de Gastroenterologia Cirúrgica, Departamento de CirurgiaUniversidade Federal de São PauloSão PauloBrazil
  6. 6.Laboratório de Citogenética Humana, Instituto de Ciências BiológicasUniversidade Federal do ParáBelémBrazil

Personalised recommendations